

Mouse Monoclonal anti-HIF-1 alpha (H1alpha67), Sample Size

Catalog Number:	NB100-105SS
Background:	<p>Hypoxia contributes significantly to the pathophysiology of major categories of human disease, including myocardial and cerebral ischemia, cancer, pulmonary hypertension, congenital heart disease and chronic obstructive pulmonary disease.</p> <p>HIF-1 is a nuclear protein involved in mammalian oxygen homeostasis. This occurs as a post-translational modification by prolyl hydroxylation. HIF-1 is a heterodimer composed of HIF-1 alpha and HIF-1 beta subunits. Both subunits are constantly translated. However, under normoxic conditions, human HIF-1 alpha is hydroxylated at Pro402 or Pro564 by a set of HIF prolyl hydroxylases, is polyubiquitinated, and eventually degraded in proteosomes. Under hypoxic conditions, the lack of hydroxylation prevents HIF degradation and increases transcriptional activity. Therefore, the concentration of HIF-1 alpha increases in the cell. In contrast, HIF-1 beta remains stable under either condition. HIF hydroxylases provide insight into hypoxic cell responses, which may be used to help isolate therapeutic targets.</p>
Alternate Names:	anti-Hypoxia-inducible factor 1 alpha antibody, anti-HIF1 alpha antibody, anti-ARNT interacting protein antibody, anti-Hif1a antibody, anti-ARNT interacting protein antibody, anti-HIF-1alpha antibody, anti-Hypoxia inducible factor 1 alpha antibody, anti-Hypoxia inducible factor 1 alpha subunit basic helix antibody
Host:	Mouse
Research Areas:	Cancer Research, Hypoxia Inducible Factors and Prolyl-Hydroxylases
Immunogen:	A fusion protein containing residues 432-528 of human HIF-1 alpha.
Clone:	H1alpha67
Isotype:	IgG2b
Localization:	Nuclear
Species Reactivity:	Human, monkey, sheep, mouse, rat, rabbit, pig, bovine and ferret HIF-1alpha. Other species have not been tested.
Uses:	<p>By Western blot, this antibody recognizes bands at 120 kDa representing HIF-1 alpha in induced tissues and cells. Multiple bands may be seen at 120 kDa representing post-translational modification of HIF-1 alpha. This antibody has also been used to immunoprecipitate human HIF-1 alpha.</p> <p>* Other applications have not been tested.</p>
Dilutions:	<p>Suggested working dilutions *</p> <p>chromatin immunoprecipitation ,</p> <p>immunohistochemistry 1:25,</p> <p>immunofluorescence ,</p> <p>immunoprecipitation Assay dependent,</p> <p>Western Blot 1:500,</p> <p>Immunohistochemistry-Frozen 1:100,</p> <p>* Investigator should determine optimal working dilutions.</p>

- Positive Controls:** Nuclear extracts are recommended. COS-7 treated and untreated nuclear extracts for positive / nega
- * [Cos7 CoCl2-treated Nuclear Extract NB800-PC26](#)
- Packaging:** 0.025 ml protein G purified Mouse ascites.
- Concentration:** 1.5 mg/ml
- Buffer:** PBS
- Preservative:** 0.05% sodium azide
- Storage:** Store at 4C. Do not freeze.
- Notes:** * The mobility of HIF-1 alpha induced by desferrioxamine or cobalt chloride treatment differs from the mobility of the hypoxia-induced protein. The reason is not known.
- Lot W is 4.0 mg/ml
Lot X is 1.5 mg/ml
- Limitations:** This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 6 months from date of receipt.
- Novus Specific References:**
1. Alberghini, A., et al. (2005) J. Biol. Chem. 280(34): 30120-30128. [Western blot, Human]
 2. Aminova, L.R., et al. (2005) J. Biol. Chem. 280(5): 3996-4003. [Western blot, Mouse]
 3. Asikainen, T. M., et al. (2006) FASEB J. 20: 1698-1700.
 4. Bateman, R. M., et al. (2007) Am J. Physiol. Heart Circ. Physiol. 293: H448-H456.
 5. Bernhardt, W. M., et al (2006) J. Am Soc. Nephrol. 17: 1970-1978.
 6. Bernhardt, W. M., et al. (2007) Am. J. Pathol. 170: 830-842.
 7. Birner, P., et al. (2000) Can. Res. 60: 4693-4696. [Immunohistochemistry-paraffin, Human]
 8. Birner, P., et al. (2001) Cancer. 92(1): 165-71, 2001. [Immunohistochemistry-paraffin, Human]
 9. Birner, P., et al. (2001) Clin. Can. Res. 7(6): 1661-1668. [Immunohistochemistry-paraffin, Human]
 10. Biswas, S., et al. (2007) Am J Physiol. Heart Circ. Physiol. 292: H758-766.
 11. Bracken, C. P., et al. (2006) J. Biol. Chem. 281: 22575-22585.
 12. Brooks, C., et al. (2007) Am J Physiol. Renal Physiol. 292: F243-252.
 13. Carroll, P. A., et al. (2006) J. Virol. 80: 10802-10812.
 14. Chade, A. R., et al. (2006) FASEB J. 20: 1706-1708.
 15. Chavez, J. C., et al. (2006) J. Neurosci. 26: 9471-9481.
 16. Chen, H., et al. (2006) Can. Res. 66: 9009-9016.
 17. Chin, BY, et al. (2007) PNAS. 0609611104.
 18. Creighton-Gutteridge, M., et al. (2007) Can. Res. 13: 1010-1018.
 19. Duyndam, M.C.A., et al. (2001) J. Biol. Chem. 276(51):48066-48076. [Western blot, Human]
 20. Fath, D. M., et al. (2006) J. Biol. Chem. 281: 13612-13619.
 21. Franco, M., et al. (2006) Can. Res. 66(7): 3639-3648.
 22. Galabova-Kovacs, G., et al. (2006) PNAS. 103: 1325-1330.
 23. Gothie, E., et al. (2000) J. Biol. Chem. 275(10):6922-6927. [Western blot, Human]
 24. Grimmer, C., et al. (2006) J. Pathol. 169: 491-502.

25. Groenman, F., et al. (2007) *J. Histochem. and Cytochem.* 55(4): 355-363.
26. Higami, Y., et al. (2006) *J. Nutrition.* 136: 343-352.
27. Hsu, T., et al. (2006) *J. Biol. Chem.* 281: 12069-12080.
28. Hu, C.-J., et al. (2006) *Mol. Cell Biol.* 26: 3514-3526.
29. Hui, A. S., et al. (2006) *J. Biol. Chem.* 281: 466-475.
30. Hwang, I. I. L., et al. (2006) *J. Virol.* 80: 10712-10723.
31. Ivan, M., et al. (2002) *PNAS.* 99: 13459-13464.
32. Ivan, M., et al. (2001) *Science.* 292(5516): 464-8. [Immunoprecipitation]
33. Jayle, C., et al. (2007) *Am. J. Physiol. Renal Physiol.* 292: F1082-1093.
34. Jeong, C.-H., et al. (2007) *J. Biol. Chem.* 282(18): 13672-13679.
35. Kamura, T., et al. (2000) *PNAS.* 97: 10430-10435.
36. Kang, S.-H., et al. (2006) *Healthscience J.* 66: 11991-11997.
37. Khan, Z., et al. (2006) *J. Pathol.* 169: 1251-1269.
38. Khurana, A., et al. (2006) *J. Biol. Chem.* 281: 35316-35326.
39. Knies-Bamforth, U.E., et al. (2004) *Can. Res.* 64:6563-6570. [Western blot, Mouse]
40. Kojima, I., et al. (2007) *J. Am. Soc. Nephrol.* 18: 1218-1226.
41. Kong, D., et al. (2005) *Can. Res.* 65: 9047-9055.
42. Lang, S. A., et al. (2007) *Molec. Can. Therap.* 6: 1123-1132.
43. LaRusch, G. A., et al. (2007) *Can. Res.* 67: 450-454.
44. Lee, K. S., et al. (2006) *Molec. Pharmac.* 35: 190-197.
45. Lee, K. S., et al. (2006) *Molec. Pharmac.* 69: 1829-1839.
46. Li, L., et al. (2006) *Can. Res.* 12: 4747-4754.
47. Liao, H., et al. (2007) *FASEB J.* 21: 935-949.
48. Lin, A. D.-Y., et al. (2006) *J. Endocrinol.* 190: 241-246.
49. Liu, W., et al. (2006) *Blood.* 107: 698-707.
50. Lukashev, D., et al. (2006) *J. Immunol.* 177: 4962-4965.
51. Luo, Y., et al. (2006) *Molec. Pharmac.* 69: 1953-1962.
52. Makino, H., et al. (2006) *Diabetes J.*, 55: 2747-2756.
53. McLaren, A. T., et al. (2007) *Am J Physiol. Regul. Integr Comp Physiol.* 292: R403-414.
54. McLaren, A., et al. (2006) *Canadian J. Anesthesiol.* 53: 26367.
55. McMahon, S., et al. (2006) *J. Biol. Chem.* 281: 24171-24181.
56. Nemetski, S. M., and Gardner, L. B. (2007) *J. Biol. Chem.* 282: 240-248.
57. Nickols, N. G., et al. (2007) *Nuc. Acid Res.* 35: 363-370.
58. Nishimura, R., et al. (2006) *J. Endocrinol.* 147: 4273-4280.
59. Oda, T., et al. (2006) *Am. J. Physiol. Cell Physiol.* 291: C104-113.
60. Pacary, E., et al. (2006) *J. Cell Sci.* 119: 2667-2678.
61. Palladino, M., et al. (2002) *Biol. Reprod.* 67: 995-1002. [Immunocytochemistry, Western blot, Rat]
62. Park, J., et al. (2003) *Clin. Can. Res.* 9:433-440. [Western blot, Human]
63. Pore, N., et al. (2006) *Can. Res.* 66: 9252-9259.
64. Pore, N., et al. (2006) *Can. Res.* 66: 3197-3204.
65. Powell, J.D. et al. (2004) *Biol. Reprod.* 70: 121-1130. [Immunocytochemistry, Rat]
66. Quintero, M., et al. (2006) *Can. Res.* 66: 770-774.
67. Rodriguez-Porcel, M., et al. (2006) *Am. J. Physiol. Heart Circ. Physiol.* 290: H978-984.
68. Ronkainen, V.-P., et al. (2007) *FASEB.* [fj.06-7294.com](http://www.faseb.org).
69. Rosenberger, C., et al. (2007) *J. Am. Soc. Nephrol.* 18: 343-351.
70. Schindl, M., et al. (2002) *Clin. Can. Res.* 8: 1831-1837. [Immunohistochemistry-paraffin, Human]

71. Shen, F., et al. (2006) *Stroke*. 37: 2601-2606.
72. Shimojo, N., et al. (2007) *Am. J. Physiol. Heart Circ. Physiol.* 293: H474-481.
73. Sumiyoshi, Y., et al. (2006) *Can. Res.* 12(17): 5112-5117.
74. Sutter, C.H., et al. (2000) *PNAS*. 97: 4748-4753.
75. Tanaka, T., et al. (2006) *J. of Gerontol. Series A*. 61: 795-805.
76. Trentin, D., et al. (2006) *PNAS*. 103: 2506-2511.
77. Veschini, L., et al. (2007) *Blood*. 109: 2565-2570.
78. Villanueva, S., et al. (2006) *Am. J. Physiol. Regul. Comp. Physiol.* 291: R1677-1687.
79. Villanueva, S., et al. *Am. J. Physiol. Regul. Comp. Physiol.* 2006; 290: R861-870.
80. Wang, J., et al. *J. Biol. Chem.* 2006; 281: 213-220.
81. Wang, R., et al. *FASEB J.* 2006; 20: 1275-1277.
82. Winner, M., et al. *Can. Res.* 2007; 67: 186-193.
83. Zagzag, D., et al. *Can. Res.* 2005; 65: 6178-6188.
84. Zampino, M., et al. *Am. J. Physiol. Heart Circ. Physiol.* 2006; 291: H957-964.
85. Zhang, X., et al. *J. Biol. Chem.* 2007; 282(15): 10873-10880.
86. Zhong, H., et al. *Can. Res.* 1999; 59: 5830-5835. [Immunohistochemistry-paraffin, Mouse, Human]
87. Zhang, H., et al. *Can. Cell.* 2007; 11: 407-420.
88. Liu, Y. et al. *J. Biol. Chem.* 2007; 10.1074/jbc.M705015200.
89. Baek, J.H. et al. *J. Biol. Chem.* 2007; 282(46): 33358-33366.
90. Baek, J.H. et al. *J. Biol. Chem.* 2007; 282(32): 23572-23580.
100. Lam, W., C.-H. Leung, et al. The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine. 2007; 72: 536-544.
101. Ide, T., Y. Kitajima, et al. The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met Signaling. *Annals of Surgical Oncology*. 2007; 14: 2600-2607.
102. Villanueva, S., et al. Inhibition of bFGF-receptor type 2 increases kidney damage and suppresses nephrogenic protein expression after ischemic acute renal failure. *Am J Physiol Regulatory Integrative Comp Physiol*, Jan 2008.
103. Engebretsen, B., et al. Acute Hypobaric Hypoxia (5486 m) Induces greater Pulmonary HIF-1 Activation in Hilltop Compared to Madison Rats. *High Altitude Medicine and Biology*. 2007; 8(4): 312-321.
104. Cheng G, Shao Z, Chaudhari B, Agrawal DK. Involvement of chloride channels in TGF-beta1-induced apoptosis of human bronchial epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. November 1, 2007; 293(5):L1339-47.
105. Black SM, DeVol JM, Wedgwood S. Regulation of fibroblast growth factor-2 expression in pulmonary arterial smooth muscle cells involves increased reactive oxygen species generation. *Am J Physiol Cell Physiol*. January 1, 2008; 294(1):C345-54.
106. McLaren, A., et al. Increased expression of HIF-1alpha, nNOS, and VEGF in the cerebral cortex of anemic rats. *Am. J. Physiol. Regul. Comp. Physiol.* 2007 292:R403-R414.
107. Zhang, H., M. Bosch-Marce, et al. Mitochondrial autophagy is a HIF-1-dependent adaptive metabolic response to hypoxia. *J. Biol. Chem.* 2008: M800102200 p.
108. Higgins, D. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. *J. Clin. Invest.* 2007; 117(12): 3810-3820. doi:10.1172/JCI30487.
109. Han S, Wang G, Qi X, Lee HM, Englander EW, Greeley JGH. A Possible Role For Hypoxia-Induced Apelin Expression in Enteric Cell Proliferation. *Am J Physiol*

Regulatory Integrative Comp Physiol. March 26, 2008:00083.2008.

110. Iwazu Y, Muto S, Fujisawa G, et al. Spironolactone Suppresses Peritubular Capillary Loss and Prevents Deoxycorticosterone Acetate/Salt-Induced Tubulointerstitial Fibrosis. *Hypertension*. March 1, 2008;51(3):749-54.

111. Murphy BJ, Kimura T, Sato BG, Shi Y, Andrews GK. Metallothionein Induction by Hypoxia Involves Cooperative Interactions between Metal-Responsive Transcription Factor-1 and Hypoxia-Inducible Transcription Factor-1{alpha}. *Mol Cancer Res*. March 1, 2008;6(3):483-90.

112. Weidemann A, Bernhardt WM, Klanke B, et al. HIF Activation Protects From Acute Kidney Injury. *J Am Soc Nephrol*. March 1, 2008;19(3):486-94. (immunohistochemistry)

113. Kaukinen A, Kuusniemi A-M, Lautenschlager I, Jalanko H. Glomerular endothelium in kidneys with congenital nephrotic syndrome of the Finnish type (NPHS1). *Nephrol Dial Transplant*. April 1, 2008;23(4):1224-32.

114. Nagao K, Taniyama Y, Kietzmann T, Doi T, Komuro I, Morishita R. HIF-1{alpha} Signaling Upstream of NKX2.5 Is Required for Cardiac Development in *Xenopus*. *J Biol Chem*. April 25, 2008;283(17):11841-9.

115. Rosenberger C, Goldfarb M, Shina A, et al. Evidence for sustained renal hypoxia and transient hypoxia adaptation in experimental rhabdomyolysis-induced acute kidney injury. *Nephrol Dial Transplant*. April 1, 2008;23(4):1135-43.

116. Frew IJ, Minola A, Georgiev S, et al. COMBINED VHLH AND PTEN MUTATION CAUSES GENITAL TRACT CYSTADENOMA AND SQUAMOUS METAPLASIA. *Mol Cell Biol*. May 12, 2008:MCB.02132-07.

117. Korgaonkar SN, Feng X, Ross MD, et al. HIF-1 Upregulates VEGF in Podocytes. *J Am Soc Nephrol*. May 1, 2008;19(5):877-83.

118. Li N, Chen L, Yi F, Xia M, Li P-L. Salt-Sensitive Hypertension Induced by Decoy of Transcription Factor Hypoxia-Inducible Factor-1{alpha} in the Renal Medulla. *Circ Res*. May 9, 2008;102(9):1101-8.

119. Lin S-K, Shun C-T, Kok S-H, Wang C-C, Hsiao T-Y, Liu C-M. Hypoxia-Stimulated Vascular Endothelial Growth Factor Production in Human Nasal Polyp Fibroblasts: Effect of Epigallocatechin-3-Gallate on Hypoxia-Inducible Factor-1{alpha} Synthesis. *Arch Otolaryngol Head Neck Surg*. May 1, 2008;134(5):522-7.

120. Ryu J, Lee C-W, Hong K-H, et al. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia. *Cardiovasc Res*. May 1, 2008;78(2):333-40.

121. Yamashita T, Ohneda O, Sakiyama A, Iwata F, Ohneda K, Fujii-Kuriyama Y. The microenvironment for erythropoiesis is regulated by HIF-2{alpha} through VCAM-1 in endothelial cells. *Blood*. May 1, 2008:11-122648.

122. Champion KJ, Guinea M, Dammai V, et al. Endothelial Function of von Hippel-Lindau Tumor Suppressor Gene: Control of Fibroblast Growth Factor Receptor Signaling. *Cancer Res* 2008;68(12):4649-4657.

123. Rimon E, Chen B, Shanks AL, et al. Hypoxia in Human Trophoblasts Stimulates the Expression and Secretion of Connective Tissue Growth Factor. *Endocrinology* 2008;149(6):2952-2958.


124. Tacchini L, Gammella E, De Ponti C, et al. Role of HIF-1 and NF-kB transcription factors in the modulation of transferrin receptor by inflammatory and anti-inflammatory signals. *J Biol Chem* 2008:M800365200.

125. Hughes D, Fu AA, Puggioni A, et al. Adventitial transplantation of blood outgrowth endothelial cells in porcine haemodialysis grafts alleviates hypoxia and decreases neointimal proliferation through a matrix metalloproteinase-9-mediated pathway--a pilot study. *Nephrol Dial Transplant* 2008:gfn433.

126. Alam H, Weck J, Maizels E, et al. Role of the PI3-Kinase and ERK Pathways in the Induction of HIF-1 Activity and the HIF-1 Target VEGF in Ovarian Granulosa Cells in response to Follicle Stimulating Hormone. *Endocrinology* 2008;en.2008-0850.
127. Hlushchuk R, Riesterer O, Baum O, et al. Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation. *Am J Pathol* 2008;173(4):1173-1185.
128. Kimura K, Iwano M, Higgins DF, et al. Stable expression of HIF-1{alpha} in tubular epithelial cells promotes interstitial fibrosis. *Am J Physiol Renal Physiol* 2008;295(4):F1023-1029.
129. Li Z, Fallon J, Mandeli J, et al. A Genetically Enhanced Anaerobic Bacterium for Oncopathic Therapy of Pancreatic Cancer. *J Natl Cancer Inst* 2008;100(19):1389-1400.
130. Norregaard R, Boedker T, Jensen BL, et al. Increased renal adrenomedullin expression in rats with ureteral obstruction. *Am J Physiol Regulatory Integrative Comp Physiol* 2008;00170.02008.
131. Trollmann R, Strasser K, Keller S, et al. Placental HIFs as markers of cerebral hypoxic distress in fetal mice. *Am J Physiol Regulatory Integrative Comp Physiol* 2008;00053.02008.
132. Mancino A, Schioppa T, Larghi P, et al. Divergent effects of hypoxia on dendritic cell functions. *Blood* 2008;112(9):3723-3734.
133. Ngan B-Y, Forte V, and Campisi P. Molecular Angiogenic Signaling in Angiofibromas After Embolization: Implications for Therapy. *Arch Otolaryngol Head Neck Surg* 2008;134(11):1170-1176.
134. Rosenberger C, Rosen S, Shina A, et al. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney.
135. Shibata R, Ueda S, Yamagishi S-i, et al. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy. *Nephrol Dial Transplant* 2008;gfn630.
136. Yang G, Sun Q, Teng Y, et al. PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor 1{alpha} signaling and endoplasmic reticulum stress. *Development* 2008;135(21):3587-3597.
- Nephrol Dial Transplant* 2008;23(11):3472-3478.
137. Hunt, T., Aslam, R., Beckert, S., et al. Aerobically Derived Lactate Stimulates Revascularization and Tissue Repair via Redox Mechanisms. *Antioxidants & Redox Signaling*. Aug. 2007:1115-1124
138. Wang, B., Zou, Y., Li, H., et al. Genistein Inhibited Retinal Neovascularization and Expression of Vascular Endothelial Growth Factor and Hypoxia Inducible Factor 1 alpha in a Mouse Model of Oxygen-Induced Retinopathy. *J. of Ocular Pharmacology and Therapeutics*. Apr. 2005:107-113.

Gene Id: 3091
Gene System: HIF1A
Reference Sequence: Q16665

Image(s)



Western analysis of COS-7 nuclear extracts (50 ug) using NB 100-105.